Document is current
Any future updates will be listed below
-
Authors
Keough, Kathleen C.
Lyalina, Svetlana
Olvera, Michael P.
Whalen, Sean
Conklin, Bruce R.
Pollard, Katherine S. http://orcid.org/0000-0002-9870-6196
-
Funding
Funding for this research was provided by:
National Institutes of Health (UM1HL098179, P01HL089707, R01MH109907, U01HL100406, P01HL089707, R01HL130533, 1R01EY028249)
Claire Giannini Fund (Claire Giannini Fund)
UCSF Discovery Fellows Program (UCSF Discovery Fellows Program)
- License Information
-
More Information
Article History
Received: 28 March 2019
Accepted: 3 August 2019
First Online: 15 August 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: BRC is the founder of Tenaya Therapeutics, a company focused on finding treatments for heart failure, including the use of CRISPR interference to interrogate genetic cardiomyopathies. BRC and KSP hold equity in Tenaya, and Tenaya provides research support for heart failure related research to BRC and KSP. All other authors declare that they have no competing interests.
